Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOPEC trial of adjuvant HIPEC after curative colon cancer surgery
NL-OMON47140Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colon cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Peritoneal recurrence-free survival. Started Mar 2015; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON47140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47140.